Goldman Sachs expects Nvidia ’beat and raise,’ lifts price target to $240
Sean Werner, chief technology officer of Biolife Solutions Inc (NASDAQ:BLFS), a $1.32 billion market cap company whose stock has gained nearly 25% over the past six months, sold 275 shares of common stock on October 20, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a price of $27.82, for a total transaction value of $7650.
Following the transaction, Werner directly owns 26037 shares of Biolife Solutions Inc.
The sale was executed under a Rule 10b5-1 trading plan, adopted on July 17, 2024, to cover tax obligations related to the vesting of restricted stock.
In other recent news, BioLife Solutions reported its second-quarter 2025 earnings, revealing a notable revenue increase of 29% year-over-year to $25.42 million, surpassing analysts’ expectations. Despite this positive revenue performance, the company posted a net loss of $15.8 million, or $0.33 per share, which was significantly larger than anticipated due to a $15.5 million in-process R&D expense related to the PanTHERA transaction. In a strategic move, BioLife Solutions sold its cold chain logistics subsidiary, SAVSU Cleo Technologies, to Peli BioThermal for $25.5 million in cash. Analyst firm KeyBanc reiterated its Overweight rating on BioLife Solutions, citing multiple growth avenues and a long-term revenue target exceeding $250 million by 2030. Additionally, H.C. Wainwright raised its price target for the company to $32 from $30, maintaining a Buy rating after the earnings announcement. Shareholders recently re-elected all seven director nominees and approved executive compensation and the appointment of Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. These developments reflect BioLife Solutions’ ongoing strategic efforts and investor confidence in its growth potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
